For a number of tumors, in particular for hepatocellular and colorectal carcinoma, the correlation of galectin-9 expression with better overall survival (OS), as well as with better progression-free survival (PFS) in gastric cancer (GC) and non-small cell lung cancer (NSCLC), was shown [20]. This evidence concerns the gene LGALS9 and colorectal carcinoma.